Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp and Decitabine in MDS/MPN and High Risk MDS
NCT05038592Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2022
- Primary completion
- Jan 2027
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2022; status: active, not recruiting.
02
Drugs
tagraxofusp
03
Conditions
chronic myelomonocytic leukemia (CMML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05038592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038592.